NCT05296278View on ClinicalTrials.gov

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

December 10, 2025

Study Completion Date

April 1, 2026

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

IBI-323 combined with bevacizumab plus Platinum

IBI-323 (30 mg/kg) ccombined with bevacizumab (15 mg/kg) plus platinum based chemotherapy ivgtt, every 21 days until disease progression

Trial Locations (1)

Unknown

RECRUITING

Hunan Cancer hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER